This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, et al. Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). Br J Cancer. 2023. https://doi.org/10.1038/s41416-023-02493-7.
Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, Chan A, et al. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer. 2023;32:47.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow SA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782–97.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, et al. Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study. Oncologist. 2021;26:e1854–61.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:242–9.
Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024. https://doi.org/10.1016/j.esmoopen.2023.102195.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, et al. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. BMC Cancer. 2022;22:915.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, et al. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study). Sci Rep. 2023;13:1257.
Author information
Authors and Affiliations
Contributions
LC, AA and MA contributed to the conceptualization of the manuscript. LC contributed to the initial draft of the manuscript. AA and MA contributed to critically review and revise the manuscript. LC, AA and MA approved the final version of the manuscript. Ethics approval and consent to participate. Not applicable.
Corresponding author
Ethics declarations
Competing interests
LC has received consulting fees from Italfarmaco, Berlin Chemie, and Helsinn. AA has received honoraria from Pfizer, BMS, LeoPharma, and Recordati. MA has received consulting fee from Accord Pharmaceuticals, Amgen, BMS, Celgene, Clinigen Group, Daiichi Sankyo, Eisai, Eli Lilly, Genomic Health, G1 Therapeutics, GlaxoSmithKline, Helsinn, Hospira, Johnson & Johnson, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Teva Pharmaceuticals, and Vifor Pharma; has received honoraria from Astellas, Bayer HealthCare Pharmaceuticals, Biocon, Boeringer Ingelheim, Cephalon, Chugai Pharmaceutical, Dr Reddy’s Laboratories, Glenmark Pharmaceuticals, Ipsen, Janssen Biotech, Kyowa Kirin Group, Sanofi, and Taiho Pharmaceutical; has received grants from Amgen, Eisai, Genomic Health, Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Tesaro, Teva Pharmaceuticals, Vifor Pharma.
Ethical approval and consent to participate
Not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Celio, L., Antonuzzo, A. & Aapro, M.S. Comment on “Dexamethasone-sparing on days 2–4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)”. Br J Cancer 130, 895–896 (2024). https://doi.org/10.1038/s41416-024-02611-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-024-02611-z
This article is cited by
-
Reply to L. Celio et al.
British Journal of Cancer (2024)